| Storm Therapeutics–IP Group: investment, 202212 financing round Series B totalling $30m incl existing + co-investor IP Group plc |
2022-12-14 |
| Storm Therapeutics–Merck (DE): investment, 202212 financing round Series B totalling $30m incl existing + co-lead investor M Ventures |
2022-12-14 |
| Storm Therapeutics–Otsuka: investment, 202212 financing round Series B totalling $30m incl existing + co-lead investor Taiho Ventures LLC |
2022-12-14 |
| Storm Therapeutics–Pfizer: investment, 202212 financing round Series B totalling $30m incl existing + co-lead investor Pfizer Ventures |
2022-12-14 |
| Storm Therapeutics–Seroba: investment, 202212 financing round Series B totalling $30m incl existing + co-investor Seroba Life Sciences |
2022-12-14 |
| Storm Therapeutics–SEVERAL: investment, 202212 financing round Series B $30m led by M Ventures + Pfizer Ventures + Taiho Ventures + CIC |
2022-12-14 |
| Storm Therapeutics–Univ Tokyo: investment, 202212 financing round Series B totalling $30m incl new + co-lead investor UTokyo IPC |
2022-12-14 |
| BehaVR–Accenture Ventures: investment, 202212 financing round Series B totalling $13m incl co-investor Accenture Ventures |
2022-12-13 |
| BehaVR–Chrysalis Ventures: investment, 202212 financing round Series B totalling $13m incl co-investor Chrysalis Ventures |
2022-12-13 |
| BehaVR–Confluent Health: investment, 202212 financing round Series B totalling $13m incl co-investor Confluent Health |
2022-12-13 |
| BehaVR–Oxford Science Enterprises: investment, 202212 financing round Series B totalling $13m incl co-lead investor Oxford Science Enterprises |
2022-12-13 |
| BehaVR–SEVERAL: investment, 202212 financing round Series B $13m led by Optum Ventures + Oxford Science Enterprises |
2022-12-13 |
| BehaVR–Thornton Capital: investment, 202212 financing round Series B totalling $13m incl co-investor Thornton Capital |
2022-12-13 |
| BehaVR–UnitedHealth: investment, 202212 financing round Series B totalling $13m incl co-lead investor Optum Ventures |
2022-12-13 |
| Green Bioactives–Javelin Ventures: investment, 202212 seed financing round totalling £2.6m incl lead investor Eos Advisory LLP |
2022-12-13 |
| Green Bioactives–Milltrust International: investment, 202212 seed financing round totalling £2.6m incl co-investor Green Earth Ventures Fund |
2022-12-13 |
| Green Bioactives–Regenerate Ventures: investment, 202212 seed financing round totalling £2.6m incl co-investor RV Agtech Fund |
2022-12-13 |
| Green Bioactives–Scotland (govt): investment, 202212 seed financing round totalling £2.6m incl co-investor Scottish Enterprise |
2022-12-13 |
| Green Bioactives–SEVERAL: investment, 202212 seed financing round £2.6m led by Eos Advisory LLP |
2022-12-13 |
| Oxford VR–BehaVR: investment, 202211 merger under BehaVR brand |
2022-12-13 |
| Horizon Therapeutics–Amgen: investment, 202212– acquisition recommended cash offer $27.8b for all outstanding shares at $116.5/share |
2022-12-12 |
| MicrofluidX–SEVERAL: investment, 202212 financing round £3.3m with Longwall Ventures + UKI2S + JB Ugland Venture + Puffin Point + Esco LifeSciences |
2022-12-08 |
| Cellesce–Danaher: investment, 202212 acquisition of Cellesce by Molecular Devices |
2022-12-06 |
| Genezen–Ramarketing: public relations, 202211 service existent Ramarketing is media contact |
2022-11-29 |
| Neogene Therapeutics–AstraZeneca: investment, 202211–202301 acquisition $200m upfront + $120 milestones on cash/debt free basis |
2022-11-29 |
| Rgenta Therapeutics–AstraZeneca: investment, 202211 financing round Series A totalling $52m incl new + lead investor AZ-CICC Fund |
2022-11-29 |
| Rgenta Therapeutics–SEVERAL: investment, 202211 financing round Series A $52m led by AZ-CICC Healthcare Investment Fund |
2022-11-29 |
| Touchlight–Gates Foundation: grant, 202211– grant to advance pre-clinical development of doggybone DNA vaccine platform |
2022-11-29 |
| V7–Air Street Capital: investment, 202211 financing round Series A totalling $33m incl existing + co-investor Air Street Capital |
2022-11-28 |
| V7–Amadeus Capital: investment, 202211 financing round Series A totalling $33m incl existing + co-investor Amadeus Capital Partners |
2022-11-28 |
| V7–Partech: investment, 202211 financing round Series A totalling $33m incl existing + co-investor Partech |
2022-11-28 |
| V7–PERSON: investment, 202211 financing round Series A totalling $33m incl ML pioneers Francois Chollet + Oriol Vinyals + Jose Valim + Ashish Vaswani |
2022-11-28 |
| V7–Radical Ventures: investment, 202211 financing round Series A totalling $33m incl co-lead investor Radical Ventures |
2022-11-28 |
| V7–SEVERAL: investment, 202211 financing round Series A $33m co-led by Radical Ventures + Temasek |
2022-11-28 |
| V7–Temasek: investment, 202211 financing round Series A totalling $33m incl co-lead investor Temasek |
2022-11-28 |
| Turbine–Accel: investment, 202211 financing round Series A totalling €20m incl existing + co-investor Accel |
2022-11-22 |
| Turbine–Day One Capital: investment, 202211 financing round Series A totalling €20m incl new + co-investor Day One Capital |
2022-11-22 |
| Turbine–Delin Ventures: investment, 202211 financing round Series A totalling €20m incl existing + co-investor Delin Ventures |
2022-11-22 |
| Turbine–Mercia: investment, 202211 financing round Series A totalling €20m incl new + co-lead investor Mercia Asset Management |
2022-11-22 |
| Turbine–Merck (US): investment, 202211 financing round Series A totalling €20m incl new + co-lead investor MSD GHI Fund |
2022-11-22 |
| Turbine–SEVERAL: investment, 202211 financing round Series A €20m co-led by Merck GHI Fund + Mercia Asset Management |
2022-11-22 |
| Turbine–XTX Markets: investment, 202211 financing round Series A totalling €20m incl existing + co-investor XTX Ventures |
2022-11-22 |
| Accession Therapeutics–SEVERAL: investment, 202211 2nd financing round £16.6m incl iGlobe Partners + Primavera Venture Partners + Birk Venture |
2022-11-21 |
| Cradle Bio–Index Ventures: investment, 202211 seed financing round totalling €5.5m incl co-lead investor Index Ventures |
2022-11-17 |
| Cradle Bio–Kindred Capital: investment, 202211 seed financing round totalling €5.5m incl co-lead investor Kindred Capital |
2022-11-17 |
| Cradle Bio–SEVERAL: investment, 202211 emerges from stealth with €5.5m seed financing round led by Index Ventures + Kindred Capital |
2022-11-17 |
| Sarcura–Lansdowne Partners: investment, 202211 seed plus financing round totalling €7m incl existing + co-lead investor Lansdowne Investment Co Cyprus |
2022-11-17 |
| Sarcura–SEVERAL: investment, 202211 seed plus financing round €7m co-led by Lansdowne Investment Co Cyprus + IST Cube |
2022-11-17 |
| Voyager Therapeutics–Touchlight: dbDNA technology, 202211– license €na to use dbDNA technology in creation of novel capsids |
2022-11-15 |
| Sartorius–SEVERAL: credit, 202211– placement of total of €650m Schulschein loans with 3, 5, 7, 10 + 13 years maturity |
2022-11-11 |
| NRG Therapeutics–Brandon Capital: investment, 202211 financing round Series A totalling £16m incl new + co-investor Brandon Capital |
2022-11-09 |
| NRG Therapeutics–Omega Funds: investment, 202211 financing round Series A totalling £16m incl new + lead investor Omega Funds |
2022-11-09 |
| NRG Therapeutics–Parkinson’s UK: investment, 202211 financing round Series A totalling £16m incl founding + co-investor Parkinson’s Virtual Biotech |
2022-11-09 |
| NRG Therapeutics–SEVERAL: investment, 202211 financing round Series A £16m led by new investor Omega Funds |
2022-11-09 |
| BC Platforms–Jolt Capital: investment, 202211 growth financing round totalling CHF20m incl new + lead investor Jolt Capital |
2022-11-08 |
| BC Platforms–SEVERAL: investment, 202211 growth financing round CHF20m led by new investor Jolt Capital |
2022-11-08 |
| Sosei–PrecisionLife: drug discovery, 202211– collab using DiseaseBank to evaluate GPCR target of Sosei Heptares for chronic diseases |
2022-11-08 |
| Citeline–Norstella: investment, 202211 merger acquisition of Citeline by Norstella |
2022-11-01 |
| Binding Site–Thermo Fisher: investment, 202210– acquisition £2.25b in cash from shareholder group led by Nordic Capital ANNOUNCED |
2022-10-31 |
| Arvinas–PhoreMost: TPD drug discovery, 202210– collab multi-target using Siteseeker + PROTAC platforms for targted protein degradation drug discovery |
2022-10-28 |
| Alto Neuroscience–SEVERAL: investment, 202210 financing round Series B $35m led by Lightswitch Capital + Alkeon Capital |
2022-10-25 |
| DJS Antibodies–AbbVie: investment, 202210 acquisition $255m upfront + milestones of DJS Antibodies Ltd by AbbVie |
2022-10-20 |
| Enhanc3D Genomics–BGF (GB): investment, 202210 financing round Series A totalling £10m incl new + co-lead investor BGF |
2022-10-20 |
| Enhanc3D Genomics–Bioqube Ventures: investment, 202210 financing round Series A totalling £10m incl existing + co-investor Bioqube Ventures |
2022-10-20 |
| Enhanc3D Genomics–IP Group: investment, 202210 financing round Series A totalling £10m incl new + co-lead investor Parkwalk Advisors |
2022-10-20 |
| Enhanc3D Genomics–OTHER: investment, 202210 financing round Series A totalling £10m incl existing private investors incl Jonathan Milner |
2022-10-20 |
| Enhanc3D Genomics–SEVERAL: investment, 202210 financing round Series A £10m led by BGF + Parkwalk Advisors |
2022-10-20 |
| Nucleome Therapeutics–Consilium: public relations, 202210 service existent by Consilium Strategic Communications |
2022-10-19 |
| Nucleome Therapeutics–JnJ: investment, 202210 financing round Series A totalling £37.5m incl new + co-investor JJDC Inc |
2022-10-19 |
| Nucleome Therapeutics–Merck (DE): investment, 202210 financing round Series A totalling £37.5m incl new + lead investor M Ventures |
2022-10-19 |
| Nucleome Therapeutics–Oxford Science Enterprises: investment, 202210 financing round Series A totalling £37.5m incl existing + co-investor OSE |
2022-10-19 |
| Nucleome Therapeutics–Pfizer: investment, 202210 financing round Series A totalling £37.5m incl new + co-investor Pfizer Ventures |
2022-10-19 |
| Nucleome Therapeutics–SEVERAL: investment, 202210 financing round Series A £37.5m led by M Ventures |
2022-10-19 |
| Nucleome Therapeutics–United Kingdom (govt): investment, 202210 financing round Series A totalling £37.5m incl new + co-investor Future Fund of BPC |
2022-10-19 |
| Empyrean Neuroscience–ERS Genomics: CRISPR technology, 202210 license to CRISPR/Cas9 technology from ERS Genomics existent |
2022-10-18 |
| Empyrean Neuroscience–SEVERAL: investment, 202210 emerges with $22m Series A financing round |
2022-10-18 |
| PBD Biotech–Foresight Group: investment, 202210 follow-on financing round totalling £2.4m incl co-lead investor Foresite Group via MEI Fund |
2022-10-17 |
| PBD Biotech–Mercia: investment, 202210 follow-on financing round totalling £2.4m incl co-lead investor Mercia via MEI Fund |
2022-10-17 |
| PBD Biotech–OTHER: investment, 202210 follow-on financing round totalling £2.4m incl private investors as co-investors |
2022-10-17 |
| PBD Biotech–SEVERAL: investment, 202210 follow-on financing round £2.4m co-led by Mercia + Foresight Group |
2022-10-17 |
| PBD Biotech–Univ Nottingham: investment, 202210 follow-on financing round totalling £2.4m incl co-investor Univ of Nottingham |
2022-10-17 |
| Andera Partners–SEVERAL: investment, 202210 final closing of BioDiscovery 6 fund at €456m |
2022-10-10 |
| Cevec–Danaher: investment, 202210 acquisition of Cevec by Cytiva |
2022-10-06 |
| Crainio–NLC Ventures: investment, 202210 existent seed investor NLC |
2022-10-05 |
| Araris Biotech–4BIO Ventures: investment, 202210 financing round totalling $24m incl existing + co-lead investor 4BIO Capital |
2022-10-04 |
| Araris Biotech–btov Partners: investment, 202210 financing round totalling $24m incl existing + co-investor btov Partners |
2022-10-04 |
| Araris Biotech–Redalpine: investment, 202210 financing round totalling $24m incl existing + co-investor Redalpine |
2022-10-04 |
| Araris Biotech–Schroders: investment, 202210 financing round totalling $24m incl existing + co-investor Schroders Capital |
2022-10-04 |
| Araris Biotech–SEVERAL: investment, 202210 financing round $24m co-led by 4BIO Capital + Pureos Bioventures |
2022-10-04 |
| Sibylla Biotech–Seroba: investment, 202210 financing round Series A totalling €23m incl co-investor Seroba Life Sciences |
2022-10-04 |
| Sibylla Biotech–SEVERAL: investment, 202210 financing round Series A €23m led by V-Bio Ventures |
2022-10-04 |
| LogicBio Therapeutics–AstraZeneca: investment, 202210– acquisition $68m cash tender offer by Alexion at $2.07/share ANNOUNCED |
2022-10-03 |
| Xund Solutions–MMC Ventures: investment, 202209 seed financing round totalling €6m incl co-lead investor MMC Ventures |
2022-09-29 |
| Xund Solutions–SEVERAL: investment, 202209 seed financing round €6m co-led by MMC Ventures + MassMutual Ventures |
2022-09-29 |
| Pheon Therapeutics–Optimum Strategic Communications: public relations, 202209 service existent by Optimum |
2022-09-28 |
| GSK–Spero Therapeutics: tebipenem HBr, 202209– license excl $66m upfront + $375m milestones + royalites ww excl JP + some other Asian countries |
2022-09-22 |
| Spero Therapeutics–GSK: investment, 202209 purchase $9m shares common stock by GSK in connection with licensing of tebipenem HBr |
2022-09-22 |
| SparingVision–SEVERAL: investment, 202209 financing round Series B €75m led by Jeito Capital + UPMC Enterprises |
2022-09-15 |
| Tridek-One–Advent Life Sciences: investment, 202209 2nd financing round totalling €16m incl existing + co-investor Advent Life Sciences |
2022-09-15 |
| Tridek-One–SEVERAL: investment, 202209 2nd financing round €16m led by Pureos Bioventures |
2022-09-15 |
![[LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal](/images/basics/lse-life-sciences-europe-portal-logo.svg){kind=logo}
1 2 3 4 5 ... 29 30 31 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
